随机双盲半脸临床试验显示溶解性透明质酸微球改善皮肤屏障功能、水合作用及弹性
Dissolving hyaluronic acid microparticles improve skin barrier function, hydration, and elasticity in a randomized split-face clinical trial
一项纳入20名健康女性的随机半脸临床试验显示,使用溶解性透明质酸微球在主要终点经皮水分流失(TEWL)和皮肤水合作用上优于无微球对照组。体外试验中,该微球使亲水性示踪剂渗透深度增加约3.8倍。研究同时观察到弹性、皱纹、真皮密度、毛孔参数及色素沉着指数等次要指标改善,且未观察到不良事件。
Introduction
The skin functions as a multifunctional organ that is essential for maintaining hydration, regulating transepidermal water loss (TEWL), and protecting the body against diverse environmental stressors1,2. The disruption of these physiological roles leads to xerosis, loss of elasticity, barrier dysfunction, delayed recovery from irritation, and pigmentary alterations1,2. Chronic exposure to ultraviolet radiation and other environmental stressors produces reactive oxygen species that exacerbate barrier impairment and visible skin aging3,4. These alterations affect the aesthetic appearance and overall comfort and increase susceptibility to the development of various dermatologic disorders1,2. Therefore, a fundamental objective in dermatologic science and cosmetic skincare research is to maintain and improve skin barrier function and hydration1,2,5,6,7. To counteract these changes and promote skin homeostasis, a broad range of cosmeceutical actives—including antioxidants, adaptogens, peptides, and hyaluronic acid (HA)—have been developed5,6,7,8,9.
Topical formulations remain the most extensively adopted approach for promoting skin health owing to their simplicity, safety, and noninvasive nature. Furthermore, their popularity parallels the continued expansion of the global skincare market1,6,7,10. The stratum corneum (SC)—a compact lipid–protein matrix—is a formidable barrier that restricts the penetration of most hydrophilic or high-molecular weight substances (> 500 Da)2,11,12. Effective penetration through the SC remains a substantial challenge despite continuous advances in formulation science11,12. Biotechnology-derived bioactive molecules, peptides, and growth factors that possess strong cosmetic and skin-rejuvenating potential have emerged; however, their efficacy remains limited because these molecules cannot effectively traverse the SC5,6,7,8,9,11,12. Hence, most topical agents are confined to the skin surface and exhibit only modest, short-lived benefits in deeper viable layers where key cellular activities associated with hydration, elasticity, and barrier renewal occur2,4,11,12. This limited transdermal efficacy warrants safe, user-friendly strategies that can improve dermal penetration without compromising skin barrier integrity11,12.
Accordingly, different physical enhancement techniques, including iontophoresis, ultrasound, microneedle (MN) arrays, and particle-based microstructures, have been investigated to improve dermal penetration beyond the SC barrier11,12,13,14,15,16,17,18,19. Energy-based approaches such as iontophoresis and ultrasound can transiently increase skin permeability; however, their reliance on dedicated devices and optimization of operating parameters may limit feasibility for routine cosmetic use12,14,15. MN arrays facilitate compound delivery into deeper cutaneous compartments11,12,13. However, their limited surface coverage and suboptimal conformity to curved facial regions reduce practicality for cosmetic applications13. Moreover, integrating conventional topical agents with MN systems presents technical challenges, as formulation viscosity, composition, and delivery kinetics are frequently incompatible with the structural and mechanical requirements of MN platforms11,12,13. In addition, MN arrays are typically applied as dry, patch-type systems, which do not align well with hydration-focused skincare routines that rely on serum-based application13.
More recently, particle-based approaches have been investigated to induce controlled, localized mechanical perturbation of the SC16,17,18,19. Among them, naturally derived or synthetic spicule-based systems have gained attention for their ability to transiently disrupt the outermost corneocyte layers and improve topical penetration16,19. However, conventional inorganic or metallic particles—including silica, alumina, and marine spicules—are rigid, nondissolving, and difficult to control in terms of size and uniformity, thereby raising concerns regarding irritation, sensitization, and environmental persistence16,17,18,19. Collectively, these limitations warrant next-generation, dissolving, and biocompatible materials that can safely enhance skin permeability without reliance on external devices, patch-based systems, or environmentally persistent particulates16,17,18,19.
We developed dissolving, star-shaped HA microparticles engineered for gentle manual rolling on the skin surface. Unlike previously reported STAR particles, which are rigid, nondissolving star-shaped particles developed primarily for topical drug, vaccine, or anesthesia delivery, the present system uses dissolving HA microparticles designed for fingertip rolling within an oil–water two-step cosmetic regimen17. The unique geometry of the HA microparticles permits transient microchannel formation under mild fingertip pressure, thereby supporting hydrophilic tracer penetration ex vivo and practical device-free application. To assess their performance, we investigated ex vivo microchannel formation and tracer penetration in porcine skin, followed by a randomized, split-face, single-center clinical study in healthy adult women (n = 20) over 4 weeks. The microparticles increased hydrophilic tracer penetration depth by approximately 3.8-fold ex vivo and produced greater improvements than the no-microparticle control in the primary outcomes of TEWL and hydration, with additional improvements observed in secondary and exploratory outcomes including elasticity, wrinkles, dermal density, pore parameters, and pigmentation indices, with no adverse events observed. Together, these results suggest that dissolving HA microparticles represent a practical, device-free approach for augmenting topical skincare regimens and improving multiple clinical skin parameters.
Methods
HA microparticle fabrication and characterization
Materials
All experiments used cosmetic-grade sodium hyaluronate (molecular weight ≈ 38 kDa; Uscarepharm, Korea) and distilled water (DW).
Fabrication
Sodium hyaluronate (50% w/v in DW) was dispensed onto custom-fabricated, star-shaped polydimethylsiloxane (PDMS) micro-molds (cavity depth ≈ 1,000 µm; arm-to-arm span ≈ 1,100 µm) and loaded into the cavities through centrifugation. The filled molds were dried at 55 °C for 5 min and then inverted into collection tubes and centrifuged again to eject the dried microparticles. The collected particles were stored in light-protected, desiccated containers at ambient temperature until use.
Geometric and mass measurements
Particle morphology—including vertical height, arm-to-arm span, and tip diameter—was investigated using optical microscopy and stereomicroscopy. Quantitative image analyses were conducted using ImageJ software with calibrated scale bars. An analytical balance (± 0.01 mg precision) was used to identify single-particle mass. At least 30 HA microparticles were analyzed to confirm batch uniformity for each parameter.
Mechanical strength
Axial compression testing was performed as a conservative mechanical screening test to evaluate the compressive load-bearing capacity of star-shaped HA microparticles during skin-contact loading. A quasi-static loading rate of 2.0 mm·min⁻1 was selected to obtain a reproducible structural failure point under slowly increasing compressive contact and to minimize impact-related fracture artifacts. Because the pointed tips and arms are the narrowest structural elements and are essential for microchannel formation, failure under axial compression was used as an indicator of tip/arm structural integrity. A universal testing machine (OmniTest 5.0, Mecmesin Ltd., UK) was used for testing. Individual HA microparticles were placed base-down on a rigid platen and compressed using a flat-ended metal probe (2 mm diameter) at 2.0 mm·min⁻1. Force–displacement curves were recorded, and the fracture force was defined as the first major drop in the curve (n ≥ 10).
Dissolution
Individual HA microparticles were immersed in DW at room temperature to verify water solubility. The endpoint was defined as complete loss of structural integrity observed under optical microscopy. The time to complete dissolution was recorded (n = 30 per condition) under static conditions and mild lateral agitation (~ 2 Hz) to mimic fingertip motion.
Ex vivo porcine skin penetration
Skin source and preparation
Commercially prepared frozen dorsal skin from one adult minipig (Cronex, Republic of Korea) was used. The exact age and body weight of the pig were not available. The skin was supplied as approximately 1.2-mm-thick split-thickness samples and trimmed into 2 × 2 cm pieces before use. The samples were stored at − 20 °C for less than 1 month before the experiments. The exact time from slaughter to tissue processing/freezing was not provided by the supplier. On the day of use, the samples were thawed in 1 × phosphate-buffered saline (PBS; pH 7.4; CHEMBIO, Korea) at room temperature. After thawing, the skin surface was visually inspected, and samples with visible cuts, tears, abrasions, or other defects were excluded. No visible subcutaneous fat was present on the supplied samples. Quantitative barrier integrity testing, such as TEWL or electrical resistance measurement, was not performed before the ex vivo experiments. For microchannel visualization and physical microchannel-dimension analysis (Fig. 3a–c), selected skin samples were pre-stained with trypan blue (Sigma-Aldrich, USA) for 30 min and rinsed with 1 × PBS for 1 min before HA microparticle rolling. Trypan blue staining has been used in microneedle and microchannel studies to visualize skin puncture sites or barrier disruption20,21. In the present study, trypan blue pre-staining was used as a visual pre-labeling step to mark pre-existing dye-accessible skin structures, including native pores, appendageal openings, and damaged or permeable surface regions. This allowed these native structures to be distinguished from newly generated HA microparticle-induced microchannels after calcein application. All ex vivo experiments were performed at room temperature under controlled laboratory conditions (25 ± 1 °C and 45% ± 5% relative humidity) to maintain consistent sample handling, manual rolling application, and fluorescence imaging conditions.
Fluorescent tracers
Calcein (0.1% w/v; Sigma-Aldrich, USA) was used to visualize aqueous penetration, whereas rhodamine B (0.1% w/v; Sigma-Aldrich, USA) was utilized for HA microparticle labeling when required. Calcein was selected as a green fluorescent hydrophilic tracer because its excitation/emission maxima are approximately 494/517 nm22. Trypan blue has a major absorbance maximum near 607 nm23 and did not generate calcein-positive green fluorescence under the imaging conditions used in this study. Therefore, pre-existing trypan blue-labeled structures appeared as dark or blue-labeled regions rather than calcein-positive signals, whereas newly formed aqueous-accessible microchannels were identified as calcein-positive puncta after HA microparticle rolling. Nevertheless, because trypan blue is an absorbing dye and may complicate fluorescence interpretation, trypan blue-pre-stained images were interpreted only for microchannel visualization and physical dimension analysis, whereas time-dependent calcein transport was analyzed separately. All solutions were freshly prepared before each experiment.
HA microparticle dosing and application
HA microparticles were suspended in an oil-based serum at 0.4% w/v. A single operator treated assigned regions through manual rolling at approximately 2 Hz for 30 s. Control regions received the same oil-based serum and fluorescent tracer without HA microparticles and were subjected to the same manual rolling procedure at approximately 2 Hz for 30 s. Thus, the rolling duration, frequency, and application procedure were matched between the HA microparticle and control conditions, and the only difference was the presence or absence of HA microparticles.
Imaging and quantification
A Leica M165 FC stereomicroscope (Leica Microsystems, Germany) with standard green and red filters was used to acquire fluorescence images. Trypan blue-assisted images in Fig. 3a–c were used for microchannel visualization and physical dimension analysis, including surface opening diameter and insertion depth. Time-dependent calcein surface coverage and penetration depth in Fig. 3d–g were analyzed separately from the trypan blue-assisted visualization experiment. For vertical diffusion assessment, treated tissues were cryosectioned at predetermined time points after calcein application. Quantification using ImageJ included (i) calcein-positive surface area fraction, defined as the percentage of pixels above the fluorescence threshold within the analyzed region of interest, from top-view images at 30, 60, 120, and 180 s and (ii) calcein distribution depth, defined as the maximum perpendicular distance from the skin surface/SC-facing side to the deepest detectable calcein-positive fluorescence signal exceeding the background intensity by ≥ 10%, from side-view sections at 5, 10, 20, 30, and 60 min. This metric represents the maximum tracer distribution depth from the skin surface and is distinct from the physical insertion depth of individual HA microparticles or the full length of an open microchannel. Because these cryosections were prepared for fluorescence imaging and were not counterstained for histological layer identification, this measurement was not used to assign calcein localization to specific skin layers such as the SC, viable epidermis, or dermis. Five skin pieces/regions prepared from the same adult minipig dorsal skin sample were used per condition for time-lapse analyses of surface coverage and penetration depth (n = 5). For microchannel opening width analysis, 18 individual microchannels created by microparticle rolling were examined (n = 18 channels). For end-point penetration depth profiling, 10 microchannels from independent rolling sites were quantified (n = 10 channels). Results are presented as mean ± standard deviation (SD).
Clinical study
Ethics and oversight
The study was approved by the Mariedm Co., Ltd. Skin Research Center Institutional Review Board (IRB No. MDSRC-2500PR-64) and was conducted in accordance with the Declaration of Helsinki, the Korean Ministry of Food and Drug Safety regulations, and the institutional standard operating procedures of the Mariedm Co., Ltd. Skin Research Center (Seoul, Korea). Written informed consent was obtained from all participants prior to enrollment. Participants also provided informed consent for publication of de-identified clinical photographs and imaging in an online open-access publication. The study was registered with the Clinical Research Information Service (CRIS), a primary registry participating in the WHO International Clinical Trials Registry Platform (ICTRP) (Registration No. KCT0011849; date of registration: April 14, 2026).
Design and participants
This randomized, assessor-blinded, split-face, single-center clinical trial included 20 healthy adult women aged 47–58 years and was conducted over 4 weeks. The study used a within-person split-face design in which each participant received the HA microparticle-containing regimen on one randomized hemiface and the no-microparticle control regimen on the contralateral hemiface. Left/right allocation was generated using a computer-generated randomization plan from randomization.com with seed 7180. Although the randomization sequence was generated before assignment, the test/control allocation was not implemented or disclosed for intervention use until after baseline assessment had been completed. Participants self-applied the assigned products according to standardized instructions; therefore, participants could not be blinded to the physical characteristics of the formulation. However, instrumental measurements and image-based data collection/quantification, including TEWL, stratum corneum hydration, skin elasticity, ANTERA 3D® CS pore/pigment analyses, and DUB® SkinScanner dermal density assessment, were performed by clinical study personnel blinded to the test/control allocation. The allocation code was revealed for statistical analysis after data collection. Assessments were performed at baseline, immediately after a single application, and at 2 and 4 weeks.
Test products and applications
Participants applied the products to the assigned cheek and eye areas according to standardized instructions. On the test side, the oil-phase serum (Part 1) containing HA microparticles was applied and gently rubbed with the fingertip for 20–30 s, followed by application of the aqueous-phase base formulation (Part 2). On the control side, Part 1 without HA microparticles was applied and gently rubbed with the fingertip for 20–30 s in the same manner, followed by the same Part 2 formulation. In the repeated-use regimen, participants applied Part 1 twice daily after cleansing and rubbed it for approximately 30 s on both the test and control sides before Part 2 application. The rubbing duration, application sequence, and application frequency were therefore matched between the two hemifaces. The only difference between the test and control products was the presence or absence of HA microparticles in Part 1. The oil-phase Part 1 formulation consisted of caprylic/capric triglyceride, triethylhexanoin, polyglyceryl-10 pentaisostearate, hydrogenated coconut oil, castor oil/IPDI copolymer, and glyceryl caprylate, with sodium hyaluronate present only in the HA microparticle-containing test formulation. Part 2 was an aqueous-based formulation consisting of water, polysorbate 80, glycerin, methylpropanediol, butylene glycol, dimethyl isosorbide, 1,2-hexanediol, niacinamide, ethoxydiglycol, polyacrylate crosspolymer-6, ethylhexylglycerin, sodium phytate, and tocopherol.
Outcome measures and instruments
Before instrumental measurements, participants washed the test sites with a cleanser and acclimatized for 30 min in a temperature- and humidity-controlled room maintained at 22 ± 2 °C and 50 ± 5% relative humidity. All measurements were performed under these controlled conditions. A closed-chamber evaporimetry device (Vapometer®, Delfin Technologies, Finland), which estimates the rate of water diffusion (g/m2/h) from the increase in relative humidity within the probe, was used to measure TEWL. A Ballistometer® BLS780 (Dia-Stron Ltd., UK) was used to assess skin elasticity, expressed as the coefficient of restitution (CoR). Periorbital wrinkle index, pore count and area, and pigmented spot area were quantified from standardized facial images obtained with ANTERA 3D® CS (Miravex, Ireland). High-frequency ultrasound (DUB® SkinScanner, Taberna Pro Medicum, Germany) was used to evaluate dermal density. Stratum corneum hydration was measured using a Corneometer® CM 825 (C + K, Germany), and the mean of three measurements from each cheek was analyzed and expressed in arbitrary units (A.U.). TEWL and stratum corneum hydration were designated as the primary clinical endpoints, reflecting the principal focus on skin barrier function and hydration. Skin elasticity, periorbital wrinkle index, dermal density, pore count, pore area, and pigmented spot area were considered secondary or exploratory outcomes.
Statistical analysis
Clinical data were analyzed using IBM SPSS Statistics version 20 (IBM Corp., Armonk, NY, USA). Data normality was assessed using the Shapiro–Wilk test together with inspection of skewness and kurtosis. When the normality assumption was satisfied, within-side changes over time were analyzed using repeated-measures analysis of variance (RM-ANOVA). When normality was not satisfied, within-side changes over time were analyzed using the Friedman test. Inter-side comparisons were assessed using RM-ANOVA for the group-by-time interaction. All tests were two-sided, and p < 0.05 was considered statistically significant. No adjustment for multiple comparisons was applied. Accordingly, findings for the secondary and exploratory outcomes should be interpreted as supportive and hypothesis-generating. Percentage change from baseline was calculated as follows: Change (%) = {Mean(after application) − Mean(before application)} / Mean(before application) × 100.
Results
Fabrication, geometry, and formulation compatibility
Centrifugal molding generated uniform, structurally intact HA microparticles (Fig. 1). Figure 1a illustrates a viscous HA solution (50% w/v) pipetted onto star-shaped PDMS micro-molds and driven into the cavities by centrifugation, followed by oven-drying to yield solid HA microparticles. The dimension callout denotes the nominal cavity geometry: arm-to-arm (tip-to-tip) span ≈ 1,100 µm, vertical height ≈ 1,000 µm, and tip diameter ≈ 180 µm. For recovery, the dried mold is mounted upside down over a collector and centrifuged, thereby releasing the dried microparticles into the vessel (Fig. 1b). Representative low- and high-magnification optical micrographs (Fig. 1c) illustrate well-defined four-arm stars with smooth faces and sharp tips. Batch-level image analysis of the recovered microparticles confirmed tight dimensional control: height: 952.9 ± 18.1 µm; arm-to-arm span: 1,110.2 ± 23.6 µm; tip diameter: 180.0 ± 1.3 µm; and single-particle mass: 0.30 ± 0.01 mg (n ≥ 30 per parameter).
Centrifugal molding, recovery, morphology, and oil-based formulation compatibility of HA microparticles. a Star-shaped PDMS mold and fabrication scheme. A viscous HA solution (50% w/v) is pipetted onto the star-shaped PDMS molds. Centrifugation drives complete filling of the cavities, followed by oven-drying to produce solid HA microparticles. The dimension callout represents the nominal geometry: arm-to-arm (tip-to-tip) span ≈ 1,100 µm, vertical height ≈ 1,000 µm, and tip diameter ≈ 180 µm. Created in BioRender. b Recovery and formulation workflow. The dried mold is mounted upside down over a collector and centrifuged to release the HA microparticles. The collected microparticles are then transferred into an oil phase to prepare the HA microparticle-in-oil serum used for clinical application. c Optical micrographs of the recovered dried microparticles at low and high magnification demonstrate a well-defined star geometry (scale bars: 2 mm and 500 µm). d Optical micrographs of HA microparticles dispersed in the oil-based serum used in the clinical study (Part 1) at low and high magnification demonstrate uniform dispersion without aggregation, deformation, or loss of tip integrity (scale bars: 2 mm and 500 µm).
To confirm compatibility with the clinical vehicle, the collected HA microparticles were transferred into the oil-based serum used in the clinical study to prepare an HA microparticle-in-oil formulation (Fig. 1b, d). Bright-field micrographs at low and high magnification (Fig. 1d) demonstrated homogeneous dispersion without aggregation, deformation, or loss of tip definition, indicating that the oil-based vehicle did not visibly change the star geometry. This suspension was stored at room temperature (25 °C) for up to 90 days. Representative optical microscopy images showed no apparent morphological deterioration, aggregation, or dissolution during storage (Supplementary Fig. S1). Furthermore, manual rolling on the skin surface under fingertip pressure remained feasible without fragmentation or structural collapse.
Mechanical robustness and dissolution behavior of HA microparticles
Axial compression testing of individual HA microparticles generated consistent force–displacement curves with an initial elastic rise followed by a distinct first peak marking structural failure (Fig. 2a, red arrow). The mean fracture force was 0.47 ± 0.04 N (n = 10), indicating reproducible compressive load-bearing behavior across particles. Because microchannel formation requires the pointed tips and arms to remain intact during skin-contact loading, this result supports the mechanical feasibility of maintaining particle geometry under compressive contact. Together with the observed microchannel formation in ex vivo porcine skin, these findings indicate that the HA microparticles possessed sufficient structural integrity for fingertip-assisted rolling under the tested gentle application conditions.
Mechanical strength and water-triggered dissolution of HA microparticles. a Schematic of the axial micro-compression setup and a representative force–displacement curve for a single HA microparticle, with the red arrow indicating the first peak at structural failure, defined as the fracture force. b Time-lapse bright-field images of single HA microparticles immersed in DW at room temperature. Top: static immersion at 1, 30, 60, and 120 s, with complete disappearance occurring by 120 s. Bottom: mild lateral agitation (~ 2 Hz) at 1, 10, 20, and 30 s, with complete disappearance occurring by 30 s (scale bars: 1 mm). c Quantification of dissolution time under static versus agitated conditions (n = 30 per group). Data are expressed as mean ± SD, with each dot representing one particle. The dissolution endpoint was defined as the loss of discernible particle morphology.
Time-lapse optical imaging captured the intended two-step functional behavior. First, particles remained structurally stable in the oil-based vehicle during application. Second, they dissolved rapidly upon subsequent contact with water, thereby recapitulating the clinical regimen (Fig. 2b). Particle contours gradually faded with complete disappearance by 120 s under static immersion, whereas disappearance occurred by 30 s with mild lateral agitation at ~ 2 Hz (≈120 cycles·min⁻1). Quantitative analysis (mean ± SD) revealed significantly accelerated dissolution with agitation (Fig. 2c): 120.3 ± 33.0 s under static conditions versus 33.9 ± 3.7 s with agitation (n = 30 per group), corresponding to a ~ 72% decrease in the dissolution time and an approximately 3.5-fold increase in the apparent dissolution rate. Furthermore, the time distribution narrowed under agitation (coefficient of variation from 27.4 to 10.9%), consistent with a more uniform endpoint, defined as loss of discernible particle structure under bright-field observation. Together with the formulation data in Fig. 1d, these results reveal that HA microparticles remain geometrically stable in the clinical oil vehicle during application and dissolve rapidly upon water exposure, thereby enabling the intended two-step regimen.
Ex vivo microchannel formation and tracer penetration induced by HA microparticles
For the microchannel visualization and physical dimension analyses shown in Fig. 3a–c, selected porcine skin samples were pre-stained with trypan blue before HA microparticle rolling. This pre-labeling step marked pre-existing dye-accessible structures, including native pores, appendageal openings, and damaged or permeable surface regions, which appeared as dark or blue-labeled regions under the imaging conditions. After HA microparticle rolling and calcein application, newly generated aqueous-accessible microchannels were identified as discrete calcein-positive puncta aligned with the rolling paths (Fig. 3a). Quantitatively, the mean microchannel opening diameter was 125.9 ± 68.5 µm (Fig. 3b; n = 18). Individual microparticles penetrated to a mean depth of 242.0 ± 41.2 µm (Fig. 3c; n = 10), indicating that microparticle application generated superficial microchannels extending below the skin surface.
HA microparticle–induced microchannels and calcein penetration in ex vivo porcine skin. a Representative bright-field and fluorescence images of trypan blue-pre-stained porcine skin after HA microparticle rolling and calcein application. Trypan blue pre-labeling marked pre-existing dye-accessible structures, whereas newly generated microchannels were identified as calcein-positive puncta aligned with the rolling paths, with lower panels showing magnified views. (scale bars: top 2,000 µm; bottom 1,000 µm). b Microchannel opening diameter at the skin surface (mean ± SD; n = 18). c Physical insertion depth of individual HA microparticles (mean ± SD; n = 10). d Top-view fluorescence images after topical calcein for 30, 60, 120, and 180 s with or without prior HA microparticle rolling (scale bar: 500 µm). e Calcein-positive surface area fraction quantified from top-view fluorescence images using ImageJ thresholding (mean ± SD; n = 5 per time point). f Side-view fluorescence sections showing vertical calcein distribution at 5, 10, 20, 30, and 60 min. The red dashed line indicates the skin surface/SC-facing side, and arrows indicate the direction of downward tracer diffusion (scale bar: 500 µm). Because these cryosections were prepared for fluorescence imaging and were not counterstained for histological layer identification, the exact boundaries of the SC, viable epidermis, and dermis could not be assigned with sufficient confidence. g Calcein distribution depth, defined as the maximum depth of detectable calcein-positive fluorescence from the skin surface/SC-facing side in side-view cryosections (mean ± SD; n = 5 per time point). Data are presented as mean ± SD. Statistical symbols indicate significant differences versus the no-microparticle control at the corresponding time point (p < 0.05).
Top- and side-view fluorescence imaging collectively demonstrated substantial enhancement of lateral surface coverage and vertical diffusion of the hydrophilic tracer after HA microparticle treatment. Fluorescence intensity and coverage in top-view images increased over 30, 60, 120, and 180 s (Fig. 3d), indicating progressive accumulation of calcein-positive signals across the treated surface. The signals were punctate and heterogeneous, consistent with multiple localized entry points formed during rolling. Image-based quantification of the calcein-positive surface area fraction reached 3.89% ± 2.29% at 180 s versus 0.48% ± 0.36% for controls (Fig. 3e; ~ 8.1-fold increase, p < 0.05). The relatively large variability in the HA microparticle group likely reflects heterogeneous manual rolling-induced microchannel formation, including local differences in particle–skin contact, rolling trajectory, skin microtopography, and local pressure. Correspondingly, cross-sectional fluorescence imaging from 5 to 60 min captured deeper vertical diffusion at every time point (Fig. 3f). Representative higher-magnification side-view cryosection images at 60 min are provided in Supplementary Fig. S2 to clarify the skin surface/SC-facing side, downward tracer diffusion, and calcein-positive distribution. In this analysis, the calcein distribution depth was defined as the maximum depth of detectable calcein-positive fluorescence from the skin surface/SC-facing side in cryosections. This metric represents tracer distribution depth rather than microparticle insertion depth or the full length of an open microchannel. The mean calcein distribution depth at 60 min was 998.6 ± 127.3 µm in the HA microparticle-treated skin compared with 265.8 ± 60.3 µm in the no-microparticle control skin (Fig. 3g; p < 0.0001; n = 5 per time point). Therefore, the greater depth observed at 60 min should be interpreted as calcein entry through microparticle-induced aqueous-accessible conduits followed by lateral and downward diffusion within the tissue, rather than as direct evidence of a ~ 1,000-µm-long open microchannel. Collectively, these results indicate that brief manual rolling with HA microparticles generates well-defined, aqueous-accessible microchannels and considerably improves lateral coverage and downward transport of a small hydrophilic molecule.
Clinical efficacy and skin parameter improvements
This 4 weeks randomized, assessor-blinded, split-face clinical study examined healthy adult women to evaluate the effects of HA microparticles on skin physiology. A total of 20 participants aged 47–58 years completed the study with no dropouts or incidence of adverse events. Standardized instrumental measurements assessed TEWL, SC hydration, skin elasticity, periorbital wrinkle index, dermal density, pore parameters, and pigmented spot area on the HA microparticle–treated and contralateral control sides. Results are expressed as mean ± SD, unless otherwise indicated.
Baseline demographic, clinical, and split-face instrumental characteristics are summarized in Table 1. Baseline TEWL, stratum corneum hydration, and skin elasticity values for the HA microparticle and control sides are presented descriptively in Table 1.
Participant flow through the trial is shown in the CONSORT 2010 flow diagram adapted for this randomized split-face within-person clinical trial (Fig. 4).
CONSORT 2010 flow diagram adapted for the randomized split-face within-person clinical trial.
Qualitative clinical and imaging observations
Representative clinical photographs and imaging, including high-frequency ultrasound (Figs. 5, 6, 7, 8), demonstrated visible improvements on the HA microparticle–treated side compared with the control side. After 4 weeks, photographs showed smoother skin texture and more pronounced periorbital wrinkle softening (Fig. 5). ANTERA 3D® CS pore maps indicated clear reductions in the pore count and area (Fig. 6). Pigment maps showed progressive fading and contraction of hyperpigmented lesions (Fig. 7). Moreover, ultrasound images displayed a denser and more homogeneous echogenic dermal band (Fig. 8). These qualitative observations are consistent with the quantitative trends described below.
Periorbital wrinkle (crow’s feet). Representative standardized photographs of the lateral canthus at baseline, week 2, and week 4 in two participants (top and bottom rows). Progressive softening of static and dynamic wrinkles is visible by week 2, with further refinement at week 4.
Skin pores. Representative ANTERA 3D® CS pore maps at baseline, week 2, and week 4 in two participants. Visible reductions in pore number and pore-affected area are observed over time.
Skin hyperpigmentation (blemishes). Representative ANTERA 3D® CS pigment maps at baseline, week 2, and week 4 in two participants. Progressive fading and contraction of hyperpigmented lesions are apparent.
Dermal density (high-frequency ultrasound, B-mode). Representative high-frequency ultrasound B-mode images of the cheek at baseline, week 2, and week 4 in two participants. The dermal band demonstrates increasing echogenicity and compaction over time.
Quantitative instrumental analysis
Primary clinical outcomes: barrier function and hydration
HA microparticle treatment led to consistent and sustained improvements in epidermal barrier function alongside increased hydration. TEWL decreased on both sides, with the treated side demonstrating greater reductions at all post-baseline visits: immediately: − 10.6% vs. − 4.9% (both p < 0.001), week 2: − 22.7% vs. − 10.1%, and week 4: − 30.6% vs. − 15.5% (p < 0.05; Fig. 9a). Hydration increased immediately and remained elevated: after a single application: + 107.1% vs. + 75.5% (both p < 0.001), week 2: + 16.7% vs. + 6.9%, and week 4: + 30.7% vs. + 14.8% (p < 0.05; Fig. 9b). These findings indicate a greater immediate change in hydration and TEWL on the HA microparticle-treated side, followed by greater sustained improvements at weeks 2 and 4. The immediate hydration values should be interpreted separately from the repeated-use changes because transient surface effects may have contributed to the Corneometer measurements.
Eight objective outcomes in a randomized split-face trial (n = 20) at baseline (0W), immediately after the first application (1A; panels a–b only), week 2 (2W), and week 4 (4W). Values are presented as mean ± SD. a TEWL. b SC hydration. c Periorbital wrinkle index (crow’s feet). d Skin pore count. e Skin pore area. f Pigmented-spot area (hyperpigmentation). g Dermal density (ultrasound echogenicity). h Skin elasticity (coefficient of restitution [CoR]). *p < 0.05 vs. 0W within the same side; †p < 0.05 for the group-by-time comparison between the test and control sides.
Secondary and exploratory clinical outcomes
Visible structural and aesthetic improvements accompanied biophysical gains. Photographs demonstrated progressive wrinkle softening on the treated side (Fig. 5), consistent with larger decreases in the periorbital wrinkle index (week 2: − 9.6% vs. − 3.3%; week 4: − 12.6% vs. − 4.9%; p < 0.001; Fig. 9c). ANTERA 3D® CS pore maps demonstrated steady and markedly greater reductions in the pore number and area (Fig. 6). Quantitatively, pore count decreased by − 24.2% and − 38.7% at weeks 2 and 4 on the treated side versus − 12.0% and − 18.0% on the control side, respectively (Fig. 9d). Furthermore, pore area showed a parallel pattern (− 31.3% and − 45.3% vs. − 15.4% and − 20.9%; Fig. 9e). Pigment maps illustrated progressive fading and contraction of hyperpigmented lesions (Fig. 7), consistent with greater reductions in the pigmented spot area (week 2: − 10.8% vs. − 5.9%; week 4: − 19.2% vs. − 9.7%; p < 0.001; Fig. 9f). High-frequency ultrasound images showed a thicker, denser, more echogenic dermal band (Fig. 8), consistent with the increase in dermal density (+ 13.0% vs. + 3.1% at week 2 and + 28.5% vs. + 9.6% at week 4; both p < 0.001; Fig. 9g). Skin elasticity, expressed as the CoR, was improved on the treated side and exceeded that on the control side at every post-baseline visit (week 2 + 4.8% vs. + 1.7%; week 4 + 8.8% vs. + 3.3%; p < 0.001; Fig. 9h), consistent with concurrent gains in hydration and dermal density.
Subjective evaluation and safety
No adverse dermatologic reactions were observed throughout the 4-week study. Participants reported no itching, prickling, burning, stinging, stiffness, or tightening, whereas investigators noted no erythema, edema, scaling, or papules. Overall tolerability was favorable under the conditions of this 4-week study.
Discussion
This study demonstrated that dissolving HA microparticles can enhance topical penetration in ex vivo porcine skin while producing measurable improvements across validated clinical endpoints without irritation. Microparticles in ex vivo porcine skin generated transient, aqueous-accessible microchannels. Top-view imaging demonstrated progressively broader lateral coverage, whereas side-view sections captured deeper tracer diffusion over the 5–60 min observation window. A randomized split-face clinical trial showed greater improvements in the primary outcomes of TEWL and hydration on the treated side, together with supportive improvements in secondary and exploratory outcomes including elasticity, wrinkle index, dermal density, pore parameters, and pigmentation.
The relatively large variability observed in microparticle-related ex vivo parameters, including microchannel opening diameter, calcein-positive surface area fraction, and penetration depth, likely reflects the dynamic and localized nature of manual rolling-based application. Unlike fixed microneedle arrays, rolling microparticles interact with the skin through repeated particle–skin contacts whose orientation, local pressure, trajectory, and spacing may vary across samples. In addition, skin microtopography, appendage distribution, and baseline barrier properties can further influence microchannel formation and tracer diffusion. Future studies could reduce this variability while preserving device-free fingertip application by further standardizing the manual application protocol, including the particle dose per unit area, dispersion uniformity in the oil vehicle, application area, rubbing duration, rolling frequency, number of passes, application direction, and operator training for consistent fingertip pressure. Stricter selection of skin samples based on quantitative barrier integrity testing, such as TEWL or electrical resistance measurement, may also reduce sample-to-sample variability.
The ex vivo and clinical findings together support a mechanism in which HA microparticles act through both physical and material-dependent effects. In ex vivo porcine skin, fingertip-like rolling generated aqueous-accessible microchannels and increased the penetration of calcein, a hydrophilic model tracer. In the clinical study, the application procedure, rubbing duration, application frequency, and Part 2 formulation were matched between the test and control sides; therefore, the greater improvements observed on the test side are consistent with an additional effect of the HA microparticle-containing regimen. These effects may be mediated by local HA release during particle dissolution, increased HA distribution through transient microchannels, and mechanical stimulation associated with microchannel formation. The longer-term improvements in elasticity, dermal density, wrinkles, pores, and pigmentation may also involve remodeling responses similar to those reported after microneedling or dermaroller-type stimulation. Thus, the present data support a combined mechanism involving HA dissolution, transient microchannel formation, and mechanical stimulation, rather than a single isolated pathway. The ~ 38 kDa sodium hyaluronate used in this study was selected as a practical low-molecular-weight HA grade for dissolving microparticle fabrication. This molecular weight falls within the low-molecular-weight HA range previously reported to show improved topical skin penetration compared with high-molecular-weight HA, and topical HA formulations containing comparable low-molecular-weight HA have been associated with improvements in hydration, elasticity, and wrinkle-related parameters. Thus, ~ 38 kDa HA was chosen to balance topical skin interaction, micromolding processability, particle integrity, and rapid water-triggered dissolution24,25.
The geometric characteristics of channels support broad compatibility with diverse topical actives. Mean opening diameters of approximately 126 µm and insertion depths of approximately 242 µm far exceed the hydrodynamic sizes of small molecules (< 2 nm), short peptides (≈1–5 nm), and many nanocarriers (≈10–200 nm)26. Thus, steric hindrance is unlikely for these classes, whereas diffusion is expected to remain within cutaneous compartments, considering the shallow insertion depth and absence of bleeding or irritation in our assays. Systemic transport was not assessed.
From a mechanical perspective, the axial fracture force of HA microparticles should be interpreted in relation to both fingertip application loads and the force required to mechanically breach the skin surface. Previous fingertip-based tactile/friction studies of topical creams maintained the applied load at approximately 0.5 N27,28, and bare-finger rubbing experiments for skin-care evaluation maintained the vertical force within 0.5–1.0 N29. The mean axial fracture force measured in the present study was 0.47 ± 0.04 N per microparticle, which is comparable to the normal load used during gentle topical rubbing. Importantly, the externally applied fingertip load during rolling is distributed across the finger–skin contact area and multiple microparticles; therefore, the force borne by an individual microparticle is expected to be lower than the total fingertip load. This suggests that the HA microparticles can withstand gentle fingertip-assisted rolling without gross structural collapse under the tested application conditions. The measured fracture force was also higher than the estimated insertion force reported for representative polymer microneedles with a 25-µm tip diameter, for which an insertion force of approximately 0.058 N per needle was calculated30. In addition, microneedle mechanics studies have shown that insertion force depends strongly on the interfacial area of the needle tip and that measured insertion forces into skin range from approximately 0.1 to 3 N, depending on microneedle geometry31. Therefore, although the absolute insertion force cannot be directly transferred from conventional microneedles to the present star-shaped HA microparticles because of differences in geometry, tip diameter, material, and rolling-mode application, these literature values provide a useful mechanical context. Together with the direct ex vivo evidence of microchannel formation, including a mean opening diameter of 125.9 ± 68.5 µm and a mean physical insertion depth of 242.0 ± 41.2 µm, the present mechanical data indicate that the HA microparticles possessed sufficient structural integrity to tolerate gentle fingertip rolling while still enabling superficial skin insertion under the tested conditions.
From a practical standpoint, this approach addresses limitations of existing enhancement modalities. MN arrays provide localized delivery. Areal coverage and conformity to curved regions remain restricted for large facial or body areas13. Energy-based methods (e.g., ultrasound and iontophoresis) transiently increase the permeability, whereas reliance on specialized devices and operator supervision decreases feasibility for routine self-application12,14,15. Dissolving HA microparticles are device-free, conform to facial contours during fingertip rolling, and are feasible for patient self-application without specialized equipment. Rapid water-triggered dissolution removes visible residues, requires no rinsing, and leaves the skin surface smooth.
A particularly relevant comparison is the STAR particle platform reported by Tadros and colleagues. STAR particles are star-shaped particles made from rigid, nondissolving materials such as aluminum oxide or stainless steel and are designed to create microscopic pores across the SC to enhance topical drug and vaccine delivery17,18. The present HA microparticles share the general concept of rolling particle-induced skin microporation but differ in material composition, dissolution behavior, and intended use. Specifically, the HA microparticles are water-dissolving, HA-based particles designed for integration with an oil-then-water cosmetic regimen. In the present study, they generated surface microchannels with a mean opening diameter of 125.9 ± 68.5 µm and a mean physical insertion depth of 242.0 ± 41.2 µm, accompanied by an approximately 3.8-fold increase in calcein tracer distribution depth versus the no-microparticle control. Thus, this system may be viewed as a dissolving, HA-based adaptation of rolling microparticle-mediated skin permeabilization for skincare applications, rather than a direct replacement for STAR particles in drug, vaccine, or anesthesia delivery.
After a single application, hydration increased on both sides, with a larger increase on the HA microparticle-treated side. However, the unusually large immediate increase in Corneometer values should be interpreted cautiously. Residual oil on the skin surface and water uptake by the dissolving HA microparticles may have temporarily affected the Corneometer measurement. Therefore, the immediate increase may not entirely reflect an increase in skin hydration itself. In contrast, the improvements observed after 2 and 4 weeks were assessed after repeated use and should be considered separately from these transient post-application effects. Similarly, the immediate decrease in TEWL may also have been influenced by short-term surface hydration or occlusion. Thus, the immediate responses were interpreted more cautiously than the sustained changes observed over 4 weeks.
The water-soluble composition of HA microparticles may also offer a practical advantage over nondissolving particulate enhancers. Because the microparticles dissolve upon water exposure, this approach is expected to reduce concerns related to persistent particulate residues compared with rigid inorganic or nondissolving particles16,17,18,19. However, environmental impact was not directly assessed in this study. From a safety perspective, the formulation was well tolerated over 4 weeks, with no adverse events observed under the conditions of this single-center clinical study.
This study has several limitations that warrant mention. This was a single-center, randomized, assessor-blinded, split-face trial that enrolled only adult women and lasted 4 weeks. Because the HA microparticle-containing formulation was physically distinguishable from the no-microparticle control formulation, participants could not be blinded to the assigned side during product use. However, instrumental outcome measurements and image-based data collection/quantification, including TEWL, stratum corneum hydration, skin elasticity, ANTERA 3D® CS pore/pigment analyses, and DUB® SkinScanner dermal density assessment, were performed by clinical study personnel blinded to the test/control allocation. The allocation code was revealed for statistical analysis only after data collection. Although the rubbing duration, application sequence, and application frequency were matched between the test and control hemifaces, fingertip pressure and the actual per-particle force during rolling were not instrumentally quantified, and this study did not include a placebo or sham microparticle control with identical geometry without HA. Therefore, the clinical effects should not be attributed exclusively to HA delivery. Potential contributions from microparticle-induced mechanical stimulation, microchannel formation, local massage-related effects, transient changes in microcirculation, surface occlusion, or acute hydration effects could not be fully excluded. Mechanical characterization was limited to axial compression testing. The comparison between the measured axial fracture force and previously reported gentle rubbing loads should therefore be interpreted as contextual mechanical support rather than a direct measurement of on-skin per-particle loading. Shear or transverse loading, which may better represent arm bending or lateral failure during rolling, was not performed. Therefore, the axial fracture force should be interpreted as a conservative screening parameter for structural robustness rather than a complete representation of rolling-mode mechanical behavior. In addition, although calcein was used to visualize aqueous-accessible microchannels in ex vivo skin, the clinical study did not directly quantify the delivery of individual non-HA formulation ingredients. Therefore, the observed clinical improvements should not be interpreted as direct evidence of enhanced delivery of co-applied non-HA actives. Ex vivo experiments used split-thickness porcine dorsal skin from a single adult minipig source and were performed under room-temperature laboratory conditions; quantitative barrier integrity testing before experimentation was not performed. Ex vivo assays also used fluorescent tracers rather than therapeutic or cosmetic actives. Human histology and microchannel-closure kinetics were not assessed. Environmental impact was not directly assessed. Safety assessment was limited to clinical observation over 4 weeks and did not include histological safety evaluation, allergy patch testing, photopatch testing, or longer-term follow-up. In vivo dissolution on human skin was inferred from aqueous experiments; hence, direct quantification under varying humidity, temperature, and sebum conditions would strengthen translational relevance. An oil-then-water regimen was used to evaluate the performance. Generalizability to other formulation types remains unknown. The study was powered for within-subject comparisons; hence, prespecified subgroup analyses were not conducted. In addition, multiple clinical outcomes were evaluated without adjustment for multiplicity; therefore, findings for secondary and exploratory outcomes should be interpreted cautiously and considered supportive rather than confirmatory.
Future studies are recommended to include multicenter, blinded studies with placebo or sham microparticle controls, such as rapidly dissolving particles with similar geometry but without HA, to separate HA-specific effects from geometry- and rolling-related mechanical effects. Head-to-head comparisons with MN and energy-based systems would also help define the relative performance of this approach. Biopsy-based analyses could define microchannel depth, closure kinetics, and tissue responses. Payload-loading and release-kinetic studies—associating in-channel distribution with pharmacodynamic outcomes—represent a logical subsequent step for drug-delivery applications. Broader assessment across formulation types and active agents will help delineate the scope and optimize usage protocols.
In summary, dissolving HA microparticles may improve topical performance by combining transient microchannel formation with rapid water-triggered dissolution. In the randomized split-face clinical study, the HA microparticle-containing regimen produced greater improvements than the no-microparticle control in the primary outcomes of TEWL and SC hydration, while secondary and exploratory outcomes showed additional supportive improvements over 4 weeks. These findings support the potential of dissolving HA microparticles as a practical, device-free approach for augmenting topical skincare regimens, while future studies should further define the underlying mechanism, long-term safety, and compatibility with broader formulation types.
Conclusion
This randomized, split-face clinical study, supported by ex vivo investigations, demonstrated that dissolving HA microparticles generated transient microchannels in porcine skin and that the HA microparticle-containing regimen was associated with greater improvements in clinical skin parameters than the no-microparticle control over 4 weeks. Compared with the control regimen, microparticle-assisted application led to greater improvements in the primary outcomes of barrier function (TEWL) and hydration. Secondary and exploratory outcomes, including elasticity, wrinkle index, dermal density, pore parameters, and pigmentation, showed additional supportive improvements, with no adverse events observed during the study. These findings support the potential of dissolving HA microparticles as a practical, device-free strategy for augmenting conventional topical regimens.
Data availability
De-identified participant data, analysis scripts (SPSS syntax), and raw imaging masks underlying the figures are available from the corresponding author upon reasonable request, subject to institutional review and a data-sharing agreement. These data are not publicly available because they contain clinical research data derived from human participants and are subject to privacy and institutional restrictions.
References
Dreno, B. et al. The science of dermocosmetics and its role in dermatology. J. Eur. Acad. Dermatol. Venereol. 28, 1409–1417 (2014).
Jiao, Q. et al. Skin homeostasis: Mechanism and influencing factors. J. Cosmet. Dermatol. 23, 1518–1526 (2024).
Verma, A. et al. Skin protection from solar ultraviolet radiation using natural compounds: A review. Environ. Chem. Lett. 22, 273–295 (2024).
Oresajo, C., Pillai, S., Manco, M., Yatskayer, M. & McDaniel, D. Antioxidants and the skin: Understanding formulation and efficacy. Dermatol. Ther. 25, 252–259 (2012).
Cavagnino, A. et al. Adaptogen technology for skin resilience benefits. Cosmetics 10, 155 (2023).
Crous, C., Pretorius, J. & Petzer, A. Overview of popular cosmeceuticals in dermatology. Skin Health Dis. 4, e340 (2024).
Lau, M., Mineroff Gollogly, J., Wang, J. Y. & Jagdeo, J. Cosmeceuticals for antiaging: A systematic review of safety and efficacy. Arch. Dermatol. Res. 316, 173 (2024).
Pintea, A. et al. Peptides: Emerging candidates for the prevention and treatment of skin senescence: A review. Biomolecules 15, 88 (2025).
Bravo, B., Correia, P., Gonçalves Junior, J. E., Sant’Anna, B. & Kerob, D. Benefits of topical hyaluronic acid for skin quality and signs of skin aging: from literature review to clinical evidence. Dermatol. Ther. 35, e15903 (2022).
Grand View Research. Skin care products market size, share & trends analysis report by product (face creams & moisturizers, sunscreen), by gender (male, female), by distribution channel, by region, and segment forecasts, 2023–2030 (Grand View Research, San Francisco, 2023).
Kim, B. et al. Transdermal delivery systems in cosmetics. Biomed. Dermatol. 4, 10 (2020).
Alkilani, A. Z., McCrudden, M. T. C. & Donnelly, R. F. Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics 7, 438–470 (2015).
Rajput, A., Patil, A., Kandhare, P. & Pawar, A. Application of microneedle arrays in cosmetics: Promises, advances, and challenges. Med. Nov. Technol. Devices 24, 100325 (2024).
Liatsopoulou, A., Varvaresou, A., Mellou, F. & Protopapa, E. Iontophoresis in dermal delivery: A review of applications in dermato-cosmetic and aesthetic sciences. Int. J. Cosmet. Sci. 45, 117–132 (2023).
Oberli, M. A., Schoellhammer, C. M., Langer, R. & Blankschtein, D. Ultrasound-enhanced transdermal delivery: Recent advances and future challenges. Ther. Deliv. 5, 843–857 (2014).
Kozlowska, J., Prus, W. & Stachowiak, N. Microparticles based on natural and synthetic polymers for cosmetic applications. Int. J. Biol. Macromol. 129, 952–956 (2019).
Tadros, A. R. et al. STAR particles for enhanced topical drug and vaccine delivery. Nat. Med. 26, 341–347 (2020).
Tadros, A. R., Prausnitz, M. R. & Felner, E. I. Rapid local anesthesia in children enhanced by STAR particles: A first-in-humans, randomized clinical trial. Drug Deliv. Transl. Res. 16, 539–548 (2026).
Kim, T. G., Lee, Y., Kim, M. S. & Lim, J. A novel dermal delivery system using natural spicules for cosmetics and therapeutics. J. Cosmet. Dermatol. 21, 4754–4764 (2022).
Sim, J. et al. Enhanced micro-channeling system via dissolving microneedle to improve transdermal serum delivery for various clinical skincare treatments. Pharmaceutics 14, 2804 (2022).
Bisgaard, S. I. et al. Dermal tissue penetration of in-plane silicon microneedles: Development, characterisation and ex vivo evaluation. Med. Nov. Technol. Devices 20, 100265 (2023).
Thermo Fisher Scientific. Calcein AM User Guide, Pub. No. MAN0019058 (2020).
Merck KGaA. Trypan blue dye content 60%, Product Information, CAS No. 72-57-1.
Essendoubi, M. et al. Human skin penetration of hyaluronic acid of different molecular weights as probed by Raman spectroscopy. Skin Res. Technol. 22, 55–62 (2016).
Pavicic, T. et al. Efficacy of cream-based novel formulations of hyaluronic acid of different molecular weights in anti-wrinkle treatment. J. Drugs Dermatol. 10, 990–1000 (2011).
Stewart, M. P. et al. Intracellular delivery by membrane disruption: Mechanisms, strategies, and concepts. Chem. Rev. 118, 7409–7531 (2018).
Ali, A. et al. Relationship between sensorial and physical characteristics of topical creams: A comparative study on effects of excipients. Int. J. Pharm. 613, 121370 (2022).
Ali, A. et al. Tactile friction of topical creams and emulsions: Friction measurements on excised skin and VitroSkin® using ForceBoard™. Int. J. Pharm. 615, 121502 (2022).
Saito, N. et al. Skin quality sensor to evaluate vibration and friction generated when sliding over skins. Int. J. Cosmet. Sci. 45, 851–861 (2023).
Park, J.-H., Allen, M. G. & Prausnitz, M. R. Biodegradable polymer microneedles: Fabrication, mechanics and transdermal drug delivery. J. Control. Release 104, 51–66 (2005).
Davis, S. P., Landis, B. J., Adams, Z. H., Allen, M. G. & Prausnitz, M. R. Insertion of microneedles into skin: Measurement and prediction of insertion force and needle fracture force. J. Biomech. 37, 1155–1163 (2004).
Acknowledgements
We thank the participants of the study. We acknowledge Enago for English language editing and BioRender for figure creation.
Funding
This research was supported by the ANCHOR through the Seoul ANCHOR Center, funded by the Ministry of Education (MOE) and the Seoul Metropolitan Government (2026-ANCHOR-01-022-05).
Author information
Authors and Affiliations
Department of Integrative Biotechnology, Yonsei University, 85 Songdogwahak-Ro, Incheon, 21983, Republic of Korea
Hyunho Hwang, JinHee Koh & Hyungil Jung
JUVIC Inc., 272 Digital-ro, Guro-gu, Seoul, 08389, Republic of Korea
Huisuk Yang & Hyungil Jung
COSMAX R&I Center, Building E & F, Pangyo Inno Valley, 255 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13486, Republic of Korea
Jeoungjin Ryu, Hyeri Ahn, Injeong Park, Junbae Lee & Chunho Park
Authors
- Hyunho Hwang
- JinHee Koh
- Huisuk Yang
- Jeoungjin Ryu
- Hyeri Ahn
- Injeong Park
- Junbae Lee
- Chunho Park
- Hyungil Jung
Contributions
Hyunho Hwang and JinHee Koh contributed equally as co–first authors. Conceptualization: Hyungil Jung, Hyunho Hwang, and JinHee Koh. Methodology: Hyunho Hwang and JinHee Koh. Microparticle fabrication and process development: JinHee Koh. Materials/resources: Hwisuk Yang. Investigation: Hyunho Hwang and JinHee Koh. Clinical investigation: Jeoungjin Ryu, Hyeri Ahn, Injeong Park, Junbae Lee, and Chunho Park. Formal analysis and data curation: Hyunho Hwang. Visualization: Hyunho Hwang and JinHee Koh. Writing—original draft: Hyunho Hwang. Writing—review & editing: all authors. Supervision and project administration: Hyungil Jung. All authors approved the final manuscript and agree to be accountable for all aspects of the work in accordance with ICMJE criteria.
Corresponding author
Correspondence to Hyungil Jung.
Ethics declarations
Competing interests
Hyungil Jung is an inventor on patents related to microneedle technologies that have been or may be licensed to JUVIC Inc. and is a founder and shareholder of JUVIC Inc. JinHee Koh was an employee of JUVIC Inc. at the time of the study; Huisuk Yang is an employee and the chief executive officer of JUVIC Inc. Jeoungjin Ryu, Hyeri Ahn, Injeong Park, Junbae Lee, and Chunho Park are employees of COSMAX R&I Center. Hyunho Hwang declares no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Hwang, H., Koh, J., Yang, H. et al. Dissolving hyaluronic acid microparticles improve skin barrier function, hydration, and elasticity in a randomized split-face clinical trial. Sci Rep 16, 30904 (2026). https://doi.org/10.1038/s41598-026-70832-8
Received: 20 March 2026
Accepted: 04 September 2026
Published: 05 October 2026
Version of record: 05 October 2026
DOI: https://doi.org/10.1038/s41598-026-70832-8
Keywords
来源:Nature 健康护理主题 · nature.com